|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Founded: November 2003
Ownership: Publicly traded on AiM of London Stock Exchange
Personnel: 34
Profile:
Proximagen is a biotechnology company focused on drug development for diseases of the Central Nervous System (CNS).
Mission Statement:
Discoveries for lifetm. We are committed to bringing novel drugs and innovative new treatments to CNS disorders as rapidly as possible, bringing new hope to the patients and value to our shareholders.
Pipeline:
Proximagen's pipeline now comprises 14 programmes derived from in-house activities, outright purchase of assets, and purchases of assets through corporate acquisition on success-based terms.
Group companies:
The Proximagen Group consists of Proximagen Neuroscience plc and its two wholly owned subsidiaries Proximagen Limited and Cambridge Biotechnology Limited.
Registered Address:
Hodgkin Building
Guy's Campus
King's College
London, SE1 1UL
United Kingdom
Proximagen Neuroscience plc is registered in England and Wales with registration number 05333020
|
|
|
|
|
|
|
